CN112220736A - 一种美白嫩肤祛皱护肤品及其制备方法 - Google Patents
一种美白嫩肤祛皱护肤品及其制备方法 Download PDFInfo
- Publication number
- CN112220736A CN112220736A CN202011307979.9A CN202011307979A CN112220736A CN 112220736 A CN112220736 A CN 112220736A CN 202011307979 A CN202011307979 A CN 202011307979A CN 112220736 A CN112220736 A CN 112220736A
- Authority
- CN
- China
- Prior art keywords
- skin
- skin care
- whitening
- tendering
- care product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000037303 wrinkles Effects 0.000 title claims abstract description 25
- 230000002087 whitening effect Effects 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 210000001808 exosome Anatomy 0.000 claims abstract description 20
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 20
- 210000002966 serum Anatomy 0.000 claims abstract description 18
- 108030001720 Bontoxilysin Proteins 0.000 claims abstract description 14
- 229940053031 botulinum toxin Drugs 0.000 claims abstract description 14
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 11
- 229960003180 glutathione Drugs 0.000 claims abstract description 11
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 11
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 11
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims abstract description 11
- 229960000401 tranexamic acid Drugs 0.000 claims abstract description 11
- 239000006285 cell suspension Substances 0.000 claims abstract description 10
- 108010024636 Glutathione Proteins 0.000 claims abstract description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 57
- 230000000694 effects Effects 0.000 abstract description 14
- 210000001061 forehead Anatomy 0.000 abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 3
- 230000037384 skin absorption Effects 0.000 abstract description 2
- 231100000274 skin absorption Toxicity 0.000 abstract description 2
- 210000004927 skin cell Anatomy 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 29
- 238000012360 testing method Methods 0.000 description 16
- 235000003969 glutathione Nutrition 0.000 description 7
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000003796 beauty Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 101000928792 Drosophila melanogaster Death-associated inhibitor of apoptosis 1 Proteins 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000002487 multivesicular body Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000037331 wrinkle reduction Effects 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 206010033474 Pain of skin Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000003131 biological toxin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940094657 botulinum toxin type a Drugs 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000004347 surface barrier Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/983—Blood, e.g. plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cosmetics (AREA)
Abstract
本发明属于护肤品技术领域，尤其涉及一种美白嫩肤祛皱护肤品及其制备方法，其原料包括玻尿酸1‑3mL、谷胱甘肽5‑8mL、肉毒素20‑50U、血清0.1‑0.3mL、外泌体生物细胞悬液0.02‑0.05mL、氨甲环酸4‑6mL与生理盐水8‑10mL；本发明产品使用方便、快捷，将产品直接注射到两侧面颊以及额头，唤醒皮肤的活力，提高皮肤的吸收能力，使皮肤细胞具有储藏大量水分的机能，同时使皮肤更具美白与光泽，减少皱纹的产生。
Description
技术领域
本发明属于护肤品技术领域，尤其涉及一种美白嫩肤祛皱护肤品及其制备方法。
背景技术
随着中国经济的不断发展，人们的生活水平也在不断改进，护肤品从奢侈品走进了普通百姓家中，成为了生活必不可少的日用品。目前，我国成为全球最有潜力的化妆品市场。而且，护肤品行业也成为我国国民经济中发展最快的行业之一。
从国内外护肤品的发展情况可以看出，美白嫩肤祛皱产品将成为未来护肤品市场发展的新趋势。但市场现有的美白抗衰老产品，很多都是以牺牲皮肤健康为代价，同时出现各种副作用，对皮肤造成损伤。
发明内容
本发明为了解决上述技术问题提供一种美白嫩肤祛皱护肤品及其制备方法。
本发明解决上述技术问题的技术方案如下：一种美白嫩肤祛皱护肤品，其原料包括玻尿酸1-3mL、谷胱甘肽5-8mL、肉毒素20-50U、血清0.1-0.3mL、外泌体生物细胞悬液0.02-0.05mL、氨甲环酸4-6mL与生理盐水8-10mL。
本发明的有益效果是：本发明产品使用方便、快捷，将产品直接注射到两侧面颊以及额头，唤醒皮肤的活力，提高皮肤的吸收能力，使皮肤细胞具有储藏大量水分的机能，同时使皮肤更具美白与光泽，减少皱纹的产生。
在上述技术方案的基础上，本发明还可以做如下改进。
进一步美白嫩肤祛皱护肤品，其原料包括玻尿酸2mL、谷胱甘肽6mL、肉毒素34U、血清0.2mL、外泌体生物细胞悬液0.03mL、氨甲环酸5mL与生理盐水9mL。
本发明还提供一种美白嫩肤祛皱护肤品的制备方法，包括以下步骤：
将原料玻尿酸1-3mL、谷胱甘肽5-8mL、肉毒素20-50U、血清0.1-0.3mL、外泌体生物细胞悬液0.02-0.05mL、氨甲环酸4-6mL与生理盐水8-10mL混合，即得本发明产品。
进一步，各原料在无菌条件下混合，混合温度控制在20-24℃，混合后进行无菌保存。
进一步，所述血清通过抽取目标人体的血液，将血液进行离心分离而提取得到的，目标人体的血液指的是使用者本身的血液或健康人体血型相符的血液。
谷胱甘肽是地球上最强的抗氧化物质之一，它是人体内自然生成的物质，具有强化人体内免疫系统的作用，在体内一直络氨酸酶的形成，持续的一直黑色素的生成，具有提高皮肤色度的效果，具有皮肤修复再生、美白、和保湿三种综合效果。
玻尿酸具有提升效果。改效果较之蛋白埋线，效果跟自然，负作用更低，而且不会发生蛋白线常见的钙化、增生等负作用。
肉毒杆菌毒素是梭状芽孢杆菌属的肉毒杆菌在厌氧条件下产生的一种生物毒素较强的高分子蛋白神经毒素。西方科学家早在1990年便报道了采用A型肉毒杆菌毒素治疗双侧咬肌肥大的经验，被认为是一种革命性新方法。从此，肉毒素开始被广泛地应用于除皱、瘦脸等整形美容外科领域。肉毒素在我国使用已有10多年，它通过失神经营养作用使咬肌萎缩、变小，从而达到瘦脸的目的。
血清能够产出具有细胞粘合功能的蛋白质，可以促进血小板大量分泌有促进伤口、组织愈合及细胞再生的9种生长因子，血清美容就是利用这一原理对血清进行加工，然后才使得血清具有了美容的功效。可以是面部皮肤变得更加光滑和细腻，同时血清蛋白美容液作用主要是修复，抗衰老，补水能力也很强，还可收缩毛孔等。血清蛋白美容液所特含的PRP血清蛋白有弹性纤维因子、血管上皮生长因子等6中增加肌肤活力的生长因子，能供给肌肤所需的全部营养。
血清美容液能够减少肌肤的氧化，让肌肤更加亮白清透，还能够强化肌肤的表面屏障，淡化肌肤表面的细纹，给肌肤补充足够的水分，给肌肤补充适量的胶原蛋白。如果肌肤状态不够好的话，可以叠加精华使用。
外泌体细胞是生物实验室里面提取植物或者动物细胞合成的再生细胞，对皮肤起到修复再生作用，外泌体是指包含了复杂RNA和蛋白质的小膜泡(30-150nm)，现今，其特指直径在40-100nm的盘状囊泡。1983年，外泌体首次于绵羊网织红细胞中被发现，1987年Johnstone将其命名为“exosome”。多种细胞在正常及病理状态下均可分泌外泌体。其主要来源于细胞内溶酶体微粒内陷形成的多囊泡体，经多囊泡体外膜与细胞膜融合后释放到胞外基质中。
所有培养的细胞类型均可分泌外泌体，且外泌体天然存在于体液中，包括血液、唾液、尿液、脑脊液和乳汁中。有关他们分泌和摄取及其组成、“运载物”和相应功能的精确分子机制刚刚开始研究。外泌体目前被视为特异性分泌的膜泡，参与细胞间通讯，对外泌体的研究兴趣日益增长，无论是研究其功能还是了解如何将其用于微创诊断的开发。
氨甲环酸能袪斑,它是通过阻断纤溶酶原分子上的赖氨酸结合点而发挥抗衰老氧化,对皮肤具有祛斑美白效果。
具体实施方式
以下对本发明的原理和特征进行描述，所举实例只用于解释本发明，并非用于限定本发明的范围。
实施例1
一种美白嫩肤祛皱护肤品，由玻尿酸1mL、谷胱甘肽5mL、肉毒素20U、血清0.1mL、外泌体生物细胞悬液0.02mL、氨甲环酸4mL与生理盐水8mL在20℃混合而成，血清是通过抽取目标人体的血液，将血液进行离心分离而提取得到的。
实施例2
一种美白嫩肤祛皱护肤品，由玻尿酸2mL、谷胱甘肽6mL、肉毒素34U、血清0.2mL、外泌体生物细胞悬液0.03mL、氨甲环酸5mL与生理盐水9mL在22℃混合而成，血清是通过抽取目标人体的血液，将血液进行离心分离而提取得到的。
实施例3
一种美白嫩肤祛皱护肤品，由玻尿酸3mL、谷胱甘肽8mL、肉毒素50U、血清0.3mL、外泌体生物细胞悬液0.05mL、氨甲环酸6mL与生理盐水10mL在24℃混合而成，血清是通过抽取目标人体的血液，将血液进行离心分离而提取得到的。
试验例
选择20位男性与20位女性，年龄在20-40岁，将40位受试者随机分成4组，分别为试验组1、试验组2与试验组3以及对照组1，试验组1-3对应注射本发明实施例1、实施例2与实施例3的护肤品，其注射位置为面颊以及额头皮肤，注射量为每一平方厘米皮肤给药0.1mL,每天一次，对照组1采用市售产品，由广州爱肤宜生物科技有限公司生产的爱肤宜水光针涂抹式，每天一次，其具体结果如下。
1、皮肤含水量评价
在同一条件下，使用皮肤水分检测仪测试受试者两侧面颊以及额头的皮肤含水量，然后计算平均值，试验结果如下表1所示：
表1皮肤含水量测试结果表
| 组别 | 使用前(％) | 使用六天后(％) |
| 试验组1 | 28.5 | 39.6 |
| 试验组2 | 27.6 | 37.5 |
| 试验组3 | 26.7 | 38.1 |
| 对照组1 | 29.1 | 32.4 |
通过表1可知本发明产品可有效提高皮肤含水量，利于嫩肤。
2、皮肤美白效果评价
比较治疗前后皮肤的颜色深浅。皮肤颜色深浅测定采用测色仪器(美能达CR-400色差计)，分别在每位受试者的前额，左颊、右颊各选取一点测量，取三点测量的明度的平均值，要求测量点无毛发、黑斑、痣等影响测量结果的因素。
与注射前(涂抹前)的明度相比，分别计算出注射(涂抹)1周后的肤色明度变化值和注射1个月后的肤色明度变化值，如下表2所示：
表2美白效果数据表
| 组别 | 1周 | 1个月 |
| 试验组1 | 11.13 | 13.24 |
| 试验组2 | 10.35 | 14.21 |
| 试验组3 | 11.31 | 11.32 |
| 对照组1 | 7.41 | 6.32 |
本发明产品在皮肤的美白效果以及时长优于市售产品，有效的改善皮肤的肤色，美白肌肤。
3、皱纹效果评价
| 组别 | 使用1周后皱纹减少率(％) | 使用2周后皱纹减少率(％) |
| 试验组1 | 4.2 | 6.3 |
| 试验组2 | 3.2 | 7.3 |
| 试验组3 | 3.8 | 8.1 |
| 对照组1 | 1.3 | 1.2 |
本发明产品在祛除皱纹的效果优于市售产品，使用本发明产品其皱纹减少率大于市售产品皱纹减少率，使受试者皮肤更具有光泽，说明本发明产品对于皱纹的祛除具有显著的效果。
以上所述仅为本发明的较佳实施例，并不用以限制本发明，凡在本发明的精神和原则之内，所作的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
Claims (5)
1.一种美白嫩肤祛皱护肤品，其特征在于，其原料包括玻尿酸1-3mL、谷胱甘肽5-8mL、肉毒素20-50U、血清0.1-0.3mL、外泌体生物细胞悬液0.02-0.05mL、氨甲环酸4-6mL与生理盐水8-10mL。
2.根据权利要求1所述一种美白嫩肤祛皱护肤品，其特征在于，其原料包括玻尿酸2mL、谷胱甘肽6mL、肉毒素34U、血清0.2mL、外泌体生物细胞悬液0.03mL、氨甲环酸5mL与生理盐水9mL。
3.一种美白嫩肤祛皱护肤品的制备方法，其特征在于，包括以下步骤：
将原料玻尿酸1-3mL、谷胱甘肽5-8mL、肉毒素20-50U、血清0.1-0.3mL、外泌体生物细胞悬液0.02-0.05mL、氨甲环酸4-6mL与生理盐水8-10mL混合，即得本发明产品。
4.根据权利要求3所述一种美白嫩肤祛皱护肤品的制备方法，其特征在于，各原料在无菌条件下混合，混合温度控制在20-24℃，混合后进行无菌保存。
5.根据权利要求3所述一种美白嫩肤祛皱护肤品的制备方法，其特征在于，所述血清通过抽取目标人体的血液，将血液进行离心分离而提取得到的。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011307979.9A CN112220736A (zh) | 2020-11-20 | 2020-11-20 | 一种美白嫩肤祛皱护肤品及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011307979.9A CN112220736A (zh) | 2020-11-20 | 2020-11-20 | 一种美白嫩肤祛皱护肤品及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112220736A true CN112220736A (zh) | 2021-01-15 |
Family
ID=74123914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011307979.9A Pending CN112220736A (zh) | 2020-11-20 | 2020-11-20 | 一种美白嫩肤祛皱护肤品及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112220736A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113913371A (zh) * | 2021-10-28 | 2022-01-11 | 三代康年(上海)医疗科技有限公司 | 一种外泌体的制备方法及由其制备得到的外泌体和应用 |
-
2020
- 2020-11-20 CN CN202011307979.9A patent/CN112220736A/zh active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113913371A (zh) * | 2021-10-28 | 2022-01-11 | 三代康年(上海)医疗科技有限公司 | 一种外泌体的制备方法及由其制备得到的外泌体和应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109350595A (zh) | 一种含有燕窝活性提取液的化妆品及其制备方法和应用 | |
| CN113616566B (zh) | 一种紧致肌肤的护肤精华液及其制备方法 | |
| CN110638740A (zh) | 一种具有调节皮肤微生态的组合物及其应用 | |
| CN111728917A (zh) | 一种护肤品及其制备方法 | |
| CN110115704B (zh) | 一种酵素组合物及其在具有美白功能化妆品中的应用 | |
| CN110522655B (zh) | 一种具有蓝色乳光和丁达尔效应的活性多肽奶基质脂质体精华水及其制备方法 | |
| CN115040461A (zh) | 一种保湿补水鲜活冻干面膜 | |
| CN110711150B (zh) | 一种多肽脂质体的制备方法及其应用 | |
| CN112807417B (zh) | 含有胶原蛋白的美白和抗皱的药物或者化妆品 | |
| CN112220736A (zh) | 一种美白嫩肤祛皱护肤品及其制备方法 | |
| CN111803395A (zh) | 自体胶原修复营养注射液及其制备方法 | |
| Weihai et al. | Effects of concentrated growth factor and nanofat on aging skin of nude mice induced by D-galactose | |
| CN110693757A (zh) | 一种含羟基酸的组合物及其制备方法和应用 | |
| KR102242215B1 (ko) | 저온 고압 효소 반응시킨 컬러 베이스 및 추출액을 함유하는 색조 화장료 조성물 | |
| CN113384482A (zh) | 一种保湿嫩肤精华露及其制备方法 | |
| US20200164037A1 (en) | Dermocosmetic composition containing synthetic platelet-like molecules to treat skin aging and stimulate hair growth | |
| CN108165527A (zh) | 一种美容护肤干细胞生长因子的富集方法及其应用 | |
| CN111759762A (zh) | 祛黑眼圈组合物、精华及其制备方法 | |
| CN110025566A (zh) | 基于干细胞培养上清液的化妆品及其应用 | |
| CN115475131A (zh) | 一种润弹抗皱面膜及其制备方法 | |
| CN113712842B (zh) | 一种组合物及其在制备化妆品及医疗器械中的应用 | |
| CN108211105A (zh) | 一种基于真皮干细胞的面部年轻化美容方法 | |
| CN113082192A (zh) | 胶原蛋白与脂肪干细胞的组合物在制备药物或者化妆品中的用途 | |
| CN103908416A (zh) | 一种护肤活性因子组合物 | |
| CN112618404A (zh) | 檀香多肽在制备护肤品中的应用及其组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20220106 Address after: 610000 No. 18, floor 18, No. 55, Qingyan street, Jinjiang District, Chengdu, Sichuan Applicant after: Chengdu aimina Enterprise Management Co.,Ltd. Address before: 610043 Room 401, 4th floor, building 1, 800 Dayue Road, Wuhou District, Chengdu City, Sichuan Province Applicant before: Chengdu Wuhou Laimei medical cosmetology clinic Co.,Ltd. |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210115 |